This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?
by Zacks Equity Research
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
by Zacks Equity Research
Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?
by Zacks Equity Research
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?
by Zacks Equity Research
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?
by Zacks Equity Research
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
by Zacks Equity Research
Zacks Value Trader Highlights: Novavax, J.C. Penney, Pier 1 Imports, Tilray and Aurora Cannabis
Should You Buy Lottery Stocks?
by Tracey Ryniec
Like playing the lottery, some stocks lure in investors with the promise of possible riches.
Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?
by Zacks Equity Research
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.05, marking a -1.95% move from the previous day.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $8.96 in the latest trading session, marking a +0.9% move from the prior day.
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Constellation Brand, Canopy Growth, Aurora Cannabis, Cronos and Tilray
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.01, marking a -1.74% move from the previous day.
Constellation Makes Big Cannabis Bet
by Daniel Laboe
Constellation Brands have been continuously adding to their stake in Canopy Growth (CGC), which is the leading player in the Canadian cannabis market. STZ just added another $4 billion investment in August bringing its total stake in Canopy to 38% ownership.
Best Performing ETFs of the First Quarter
by Neena Mishra
Major indexes posted their best quarterly performance since the financial crisis; here are some ETFs that soared during the quarter
Short Sellers and Easing Rules Boost Pot ETF Higher
by Sweta Killa
Along with easing rules, short-selling of the stocks led to the spike in the pot ETF.
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher? (Revised)
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
Aurora Cannabis Inc. (ACB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $9.18 in the latest trading session, marking a +1.32% move from the prior day.
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher?
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
Buy Walgreens (WBA) Stock Ahead of Q2 Earnings, Before CBD Push?
by Benjamin Rains
Shares of Walgreens Boots Alliance, Inc. (WBA) have fallen roughly 9% this year, which stands in contrast to the market's nearly 13% climb and its industry's 4.5% average gains. But is it time to buy WBA stock ahead of earnings?
Marijuana ETF Outperforms in Q1: 6 Stocks Leading the Rally
by Sweta Killa
Though most of the stocks in the marijuana ETF portfolio delivered strong returns, a few were the real stars, soaring more than 60% in the first quarter.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $9.15, marking a -1.05% move from the previous day.
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed at $9.80 in the latest trading session, marking a -1.61% move from the prior day.
Company News For Mar 14, 2019
by Zacks Equity Research
Companies In The News Are: JPM, ACB, FCAU, CLDR